Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to achieve 12‐month remissionSubgroup: focal onset seizures… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to achieve 12‐month remissionSubgroup: generalisedonset tonic… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Mortality. · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in mortality. compared with placebo (moderate certainty).
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Alteplase may leads to higher serious adverse events compared with urokinase (low certainty).
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Fibrinolytics may leads to lower referral for thoracic surgery. compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in mortality compared with urokinase (low certainty).
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in serious adverse events compared with urokinase (low certainty).
1 finding from 1 review
All‐cause mortality · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in mortality compared with urokinase (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with CF
1 finding from 1 review
Direct measures of mucus clearance · adults and children with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exercise capacity · adults and children with CF
1 finding from 1 review
General well‐being · adults and children with CF
1 finding from 1 review
LCI · adults and children with CF
1 finding from 1 review
Adverse events · adults and children with CF
1 finding from 1 review
no estimate extracted
22 participants
Low
FEV1 % predicted: absolute change from baseline · adults and children with CF
1 finding from 1 review
Pulmonary exacerbations · adults and children with CF
Summary of findings ‐ PEP leads to lower number of respiratory exacerbations compared with HFCWO (high certainty).
1 finding from 1 review
Direct measures of mucus clearance · adults and children with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found